Efficacy and safety of canakinumab in patients with Adult-Onset Still’s Disease: Results from an open-label Phase III study in Japan
Although the primary endpoint was not met, week 28 analysis showed that canakinumab treatment led to improvements in various efficacy outcome measures in Japanese patients with AOSD, with no unexpected safety signals.
Institutions
- Kanazawa University (JP)
- Novartis (Switzerland) (CH)
- Kyorin University (JP)
- Keio University (JP)
- Hokkaido University (JP)
- St. Luke's International Hospital (JP)
- Chiba University Hospital (JP)
- ENT and Allergy (US)
- Kanazawa University Hospital (JP)
- Novartis (Japan) (JP)
- Nagasaki University (JP)
- Saitama Medical University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1093/mr/roag026
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00